Filtered By:
Specialty: Hematology
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 643 results found since Jan 2013.

Long-term outcomes of left atrial appendage occlusion in high-risk atrial fibrillation patients: 4-year follow up data
AbstractLong-term follow-up data of left atrial appendage (LAA) occlusion in patients with atrial fibrillation (AF) are sparse. To address these data gaps, we analysed the 4-year outcomes of AF patients following LAA occlusion. The was a retrospective cohort study of high-risk patients with AF who underwent successful implantation of the Amulet device at our center between 2014 and 2017. Study endpoints were the rate of stroke, major bleeding and all-cause mortality. We included 71 patients (35.2% females) with a median age of 78 (IQR 73 –82) years. Over a median follow-up period of 46 (IQR 19–56) months, the annual ra...
Source: Journal of Thrombosis and Thrombolysis - November 9, 2020 Category: Hematology Source Type: research

Effectiveness and safety of apixaban vs. rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus
CONCLUSIONS: Among patients with NVAF and T2DM, apixaban was associated with a similar risk of stroke, and a lower risk of major bleeding compared with rivaroxaban.PMID:35292949 | DOI:10.1055/a-1798-2116
Source: Thrombosis and Haemostasis - March 16, 2022 Category: Hematology Authors: Krishna Roy Chowdhury Jonathan Michaud Oriana Hoi Yun Yu Hui Yin Laurent Azoulay Christel Renoux Source Type: research

Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study
CONCLUSION: Intracranial bleeding, ischemic stroke, and mortality risks were higher for patients with CVT than matched patients with VTE and the general population, particularly within 6 months after diagnosis.PMID:35688451 | DOI:10.1055/s-0042-1743473
Source: Thrombosis and Haemostasis - June 10, 2022 Category: Hematology Authors: Anne Gulbech Ording Flemming Skj øth S øren Due Andersen Torben Bjerregaard Larsen Source Type: research

Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis
CONCLUSION: In patients with AF and polypharmacy, NOACs showed advantages over VKAs in stroke or systemic embolism and any bleeding, and were comparable to VKAs for major bleeding, ischemic stroke, all-cause death, intracranial hemorrhage, and gastrointestinal bleeding.PMID:37399842 | DOI:10.1055/s-0043-1770724
Source: Thrombosis and Haemostasis - July 3, 2023 Category: Hematology Authors: Yuxiang Zheng Siyuan Li Xiao Liu Gregory Y H Lip Linjuan Guo Wengen Zhu Source Type: research

Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4 –5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study
AbstractThe role of direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) and stage 4 –5 chronic kidney disease (CKD) is controversial. Electronic medical records from 2012 to 2021 were retrieved for patients with AF and stage 4–5 CKD receiving oral anticoagulants. Patients were separated into those receiving DOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) or vitamin K ant agonists (VKA). Primary outcomes included ischemic stroke (IS), systemic thrombosis (SE), major bleeding, gastrointestinal bleeding, hemorrhagic stroke, acute myocardial infarction, cardiovascular death, and all-cause dea...
Source: Journal of Thrombosis and Thrombolysis - August 21, 2023 Category: Hematology Source Type: research

Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion
Conclusion: We found a low risk for stroke in the absence of postoperative bridging. For patients with device replacement surgery reversal of the anticoagulant effect at the time of procedure might reduce the risk for pocket hematoma, but this requires prospective evaluation including the risk of thromboembolism.
Source: Thrombosis Research - January 31, 2013 Category: Hematology Authors: S. Schulman, J. Schoenberg, S. Divakara Menon, A.C. Spyropoulos, J.S. Healey, J.W. Eikelboom Tags: Clinical Studies Source Type: research

Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation.
In conclusion, in patients with AF and high thromboembolic risk after stent implantation, use of OAC was independently associated with decreased risk of subsequent death/stroke/systemic TE, suggesting that OAC should be systematically used in this patient population. PMID: 23846210 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 11, 2013 Category: Hematology Authors: Bernard A, Fauchier L, Pellegrin C, Clementy N, Saint Etienne C, Banerjee A, Naudin D, Angoulvant D Tags: Thromb Haemost Source Type: research

Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial.
In conclusion, the HAS-BLED score demonstrated significant discriminatory performance for "any clinically relevant bleeding" in anticoagulated patients with AF, whilst the CHADS2 and CHA2DS2-VASc scores did not. Bleeding risk assessment should be made using a specific bleeding risk score such as HAS-BLED, and the stroke risk scores such as CHADS2 or CHA2DS2-VASc scores should not be used. PMID: 24048467 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 19, 2013 Category: Hematology Authors: Apostolakis S, Lane DA, Buller H, Lip GY Tags: Thromb Haemost Source Type: research

Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta‐analysis
ConclusionMortality in patients treated by thrombolytic therapy for valve prosthesis thrombosis is significantly lower than in patients treated surgically. As we cannot yet ascertain whether this difference is due to the treatment alone, more studies now are necessary to further clarify these findings.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 2, 2014 Category: Hematology Authors: F. M. Castilho, M. R. Sousa, A. L. P. Mendonça, A. L. P. Ribeiro, F. M. Cáceres‐Lóriga Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta-analysis.
CONCLUSION: Mortality in patients treated by thrombolytic therapy for valve prosthesis thrombosis is significantly lower than in patients treated surgically. As we cannot yet ascertain whether this difference is due to the treatment alone, more studies now are necessary to further clarify these findings. This article is protected by copyright. All rights reserved. PMID: 24698327 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 2, 2014 Category: Hematology Authors: Castilho FM, Sousa MR, Mendonça AL, Ribeiro AL, Cáceres-Lóriga FM Tags: J Thromb Haemost Source Type: research

Individualized antithrombotic therapy.
Conclusion: An extensive therapeutic arsenal to interfere with clot formation requires an individualized approach considering the disease condition and co-morbidities of the patient, the anticoagulants' and patientcharacteristics. This review builds on and extens previous publications of the authors on this topic. PMID: 25597592 [PubMed - as supplied by publisher]
Source: Hamostaseologie - January 19, 2015 Category: Hematology Authors: Lüscher TF, Steffel J Tags: Hamostaseologie Source Type: research

Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial
Conclusions: Based on AVERROES trial results, among patients with AF unsuitable for warfarin therapy, apixaban use was estimated to be associated with a mean medical cost avoidance of US$735 in a patient-year relative to aspirin. The primary driver was the significant reduction in ischemic stroke rate. The medical cost reduction associated with apixaban use was consistent in sensitivity analyses.
Source: Clinical and Applied Thrombosis/Hemostasis - February 27, 2015 Category: Hematology Authors: Amin, A., Deitelzweig, S., Jing, Y., Makenbaeva, D., Wiederkehr, D., Lin, J., Graham, J. Tags: Original Articles Source Type: research

Activated protein C {beta}-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury
In this study, a recombinant APC variant (APCN329Q) mimicking the naturally occurring APC-β plasma glycoform was found to exhibit superior PAR1 proteolysis at a cleavage site that selectively mediates cytoprotective signaling. APCN329Q also enhanced integrin αMβ2-dependent PAR1 proteolysis to exert significantly improved antiinflammatory activity on macrophages compared with wild-type APC. Recent therapeutic applications of recombinant APC in ischemic stroke models have used APC variants with limited anticoagulant activity to negate potential bleeding side effects. Using a mouse model of ischemic stroke and...
Source: Blood - August 13, 2015 Category: Hematology Authors: Gleeson, E. M., Dichiara, M. G., Salicio, A., Quinn, L. M., Drakeford, C., Russell, S. E., Walsh, P. T., Orbe, J., Hermida, J., Smith, O. P., O'Donnell, J. S., Montes, R., Preston, R. J. S. Tags: Thrombosis and Hemostasis, Brief Reports Source Type: research